Radiation Oncology · 2019 · 20 citations · 25 references
MedicineOncologyRadiation OncologyChemotherapyClinical Radiation OncologyThoracic OncologyChemotherapy Toxicity ManagementConcurrent ChemoradiationRadiation PneumonitisRadiation TherapyToxicity GradingToxicity ManagementAcute Radiation InjuryAcute Radiation PneumonitisCancer Therapy-related Pulmonary ToxicityChemotherapy Toxicity Risk AssessmentChemotherapy-induced Pulmonary ToxicityConcurrent Chemoradiotherapy ToxicityGemcitabine-based TherapyPulmonary Toxicity Grading
Abstract Objectives To observe the risk factors affecting the occurrence of RP after gemcitabine-based induction chemotherapy. Methods Between January 2010 and December 2017, patients with NSCLC received gemcitabine or docetaxel chemotherapy, followed by radiotherapy at Zhejiang cancer hospital were enrolled in this study. Patients were treated with gemcitabine or docetaxel induction chemotherapy, followed by radiotherapy or concurrent chemoradiotherapy. Acute radiation pneumonitis was scored post chemoradiotherapy. Results One hundred and eighty-four patients with NSCLC were included in the gemcitabine group and 144 in the docetaxel group. The gemcitabine group experienced a higher incidence of grade ≥ 2 RP, compared with docetaxel group (25.5% Vs. 13.2%, P = 0.005). The optimal cutoff values of lung V 5 , V 20 , V 30 and MLD were set at 44% (AUC [area under the curve] = 0.593), 24% (AUC = 0.607), 14.2% (AUC = 0.622) and 1226 cGy (AUC = 0.626). On multivariate analysis, only lung V 30 was identified as a predictor for grade ≥ 2 RP ( P = 0.03). The grade ≥ 2 RP rate was only 9.4% for the low-risk group (Lung V 5 ≤ 44%, V 20 ≤ 24%, V 30 ≤ 14.2%, and MLD ≤ 1226 cGy) in patients received gemcitabine induction chemotherapy. Conclusions Gemcitabine chemotherapy before thoracic radiotherapy in NSCLC patients was related to a higher incidence of grade ≥ 2 RP, compared with docetaxel chemotherapy. The Lung dose-volume variable V 30 was the best predictor of grade ≥ 2 RP.
25
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 3.2K citations
Medicine, Oncology, Pharmacology +16
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text
Walter J. Curran, Rebecca Paulus, Corey J. Langer et al. · JNCI Journal of the National Cancer Institute · 2011 · 1.2K citations · Full text
Stephen G. Chun, Chen Hu, Hak Choy et al. · Journal of Clinical Oncology · 2016 · 748 citations · Full text
Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012 · 614 citations · Full text
Medicine, Oncology, Pharmacotherapy +13